The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

media.springer/m685/springer-static/imag

Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma - ScienceDirect

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer

Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer, World Journal of Surgical Oncology

Identification of Ultrasound-Sensitive Prognostic Markers of LAML and Construction of Prognostic Risk Model Based on WGCNA

Clinical application of the AMOY 9-in-1 panel to lung cancer patients - ScienceDirect

IJMS, Free Full-Text

Frontiers LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report

Characterization of the genomic alterations in poorly differentiated thyroid cancer

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC

Lung cancer in patients who have never smoked — an emerging disease

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

Review: biological implications of oncogenic rearrangements in non-small cell lung cancer - Di Marco - Precision Cancer Medicine